Deltaran® [Delta-sleep peptide]

The use of Deltaran® makes it possible to compensate for the deficiency of endogenous neuroprotectors in the body, which ensures unimpaired functioning of the central nervous system in extreme situations.

Dosage and Administration

The content of 1 ampoule of Deltaran® is dissolved in 0.5 ml of boiled water of room temperature (10-12 drops or half a pipette) immediately before use and is pipetted into both nasal passages with an interval of 15-20 minutes. After an intranasal administration, the drug reaches the thalamic nuclei in 1.5-2 minutes. The stabilizing effect develops, depending on the level of endogenous peptides, within from 3 minutes to 1.5 hours.

The resulting solution is utilized in full and cannot be stored. The pipette is washed thoroughly with boiled water after use.

1-3 ampoules per day are used for 5-10 days for the prevention and treatment of a disease.

For the detailed information on the drug administration please refer to the description.


Store in a dark place, at a temperature from 2 ° C (35.6 ° F) to 15 ° C (59 ° F).


The drug does not have a sedative action.

Adequate foreign analogues do not exist. Ciba-Gelgy Acea 1024 drug has a narrower spectrum of action, is not a direct derivative of DSIP and contains substances that are alien to the human body, thus it has a number of side effects, including allergenic reactions. Hoffman La Roshe (AG Clinalfa) DSIP Clinalfa drug has a narrower scope (narcology and sleep disorders), its method of use (intravenous) is less convenient, in addition, it is several times more expensive than Deltaran®.

 Read full instruction here

Deltaran® is a representative of the class of neuroprotectors. It has a powerful antioxidant, stress protective and antidepressant effect. It protects neurons from the destruction by toxic, infectious and other damaging agents, and also prevents the death of nerve cells because of stress.


Deltaran® is based on synthetic nonapeptide - an analogue of one of the most important natural endogenous peptides - discovered in 1977 by Swiss scientists Monnier M and Schoenenberg GA - the regulatory delta-sleep peptide (DSIP: delta-sleep inducing peptide) with a stabilizing effect on the cell homeostasis. DSIP in free and bound form is present in peripheral organs, tissues and body fluids, hypophysis, hypothalamus and in limbic system of the brain. One of the most impressive features of its wide multifunctional action is its pronounced stress-protective and adaptogenic activity.

The peptide-based Deltaran® drug was originally developed as an anti-alcohol medication. The development was carried out in the Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry together with the Pharmacology Institute of the Russian Academy of Medical Sciences in the 1980s. After conducting experimental and clinical studies, the drug Deltaran® was registered by the Ministry of Health of the Russian Federation in July 1998.

The main mechanism of action of the drug is the compensation for the deficiency of DSIP, which protects neurons from the destruction, resulting from psycho-emotional or systemic stress, toxic effects or aging. Protecting the central nervous system from damaging effects, Deltaran® is able to radically change the course of a large number of diseases in a favourable direction, to increase the effectiveness of standard medicines and to prevent the development of complications. In clinical trials and testing, Deltaran® has shown a number of positive effects:

  • Pronounced stress-protective and adaptogenic effect;
  • Increased body resistance to adverse stress factors and pathological conditions of different etiologies;
  • Antidepressant and anticonvulsant effects;
  • Normalization of sleep;
  • Antitoxic properties;
  • Improving mental and physical performance;
  • Limitation of vegetative and cardiovascular disorders in case of stress;
  • Reduction of the primary pathological craving for alcohol and drugs, and manifestations of alcohol withdrawal;
  • Complex therapy for neuroborreliosis, multiple sclerosis, cerebral palsy. [Biomedical Journal (2001)]

  1. Schoenenberg, Monnier (1977) Characterization of a delta-electroencephalogram (-sleep) -inducing peptide.  
  2. Sudakov et al (1983) Delta-sleep-inducing peptide (DSIP) as a factor facilitating animals' resistance to acute emotional stress. 6687936
  3. Schoenenberg (1984) Characterization, properties and multivariate functions of delta-sleep-inducing peptide (DSIP).
  4. Graf, Kastin (1984) Delta-sleep-inducing peptide (DSIP): a review.
  5. Graf, Kastin (1986) Delta-sleep-inducing peptide (DSIP): an update.
  6. Westrin (1998) High delta sleep-inducing peptide-like immunoreactivity in plasma in suicidal patients with major depressive disorder.
  7. Biomedical Journal (2001)
  8. Khvatova et al (2003) Delta sleep inducing peptide (DSIP): effect on respiration activity in rat brain mitochondria and stress protective potency under experimental hypoxia.
  9. Popovich et al (2003) Effect of delta-sleep inducing peptide-containing preparation Deltaran on biomarkers of aging, life span and spontaneous tumor incidence in female SHR mice.
  10. Konorova et al (2006) Deltaran prevents an adverse effect of emotional stress on the course of cerebral ischemia in low-resistant animals.
  11. Koplik et al (2008) Delta sleep-inducing peptide and Deltaran: potential approaches to antistress protection.
  12. Grigorchuk, Umriukhin (2012) Neuronal activity in the dorsal hippocampus after lateral hypothalamus stimulation: effects of delta-sleep-inducing peptide.
  13. Kutilin (2014) Effect of delta sleep-inducing peptide on the expression of antioxidant enzyme genes in the brain and blood of rats during physiological aging.
  14. Banks (2015) Peptides and the blood-brain barrier.
  15. Bobyntsev et al (2016) Effect of Delta Sleep-Inducing Peptide on Functional State of Hepatocytes in Rats During Restraint Stress.

Type: Unknown Type